✦ LIBER ✦

2.210 Determining the benefit of levodopa/carbidopa/entacapone (Stalevo®) on the pharmacokinetic profile of levodopa: a randomized, crossover, multicentre study in patients with Parkinson's disease

✍ Scribed by S. Kaakola; J. Ellmén; R. Marttila; V. Kaasinen; P. Hartikainen; J. Lyytinen; J. Hänninen; K. Korpela; M. Kuoppamäki

Book ID: 117752861
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 54 KB
Volume: 13
Category: Article
ISSN: 1353-8020
DOI: 10.1016/s1353-8020(08)70621-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Effect of entacapone, a COMT inhibitor,

Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease

✍ V. V. Myllylä; K. A. Sotaniemi; A. Illi; K. Suominen; T. Keränen 📂 Article 📅 1993 🏛 Springer 🌐 English ⚖ 563 KB

In an open, randomised, cross-over study we investigated the effect of a single 200 mg oral dose of entacapone, a novel catechol-O-methyltransferase (COMT) inhibitor, on the pharmacokinetics and metabolism of levodopa/carbidopa, and on the cardiovascular responses (blood pressure and pulse rate vari

Immediate Versus Delayed Switch From Lev

Immediate Versus Delayed Switch From Levodopa/Carbidopa to Levodopa/Carbidopa/Entacapone: Effects on Motor Function and Quality of Life in Patients With Parkinson's Disease With End-of-Dose Wearing Off

✍ Lew, Mark F.; Somogyi, Monique; McCague, Kevin; Welsh, Mickie; on behalf of the 📂 Article 📅 2011 🏛 Informa plc 🌐 English ⚖ 339 KB

Efficacy and tolerability of entacapone

Efficacy and tolerability of entacapone in patients with Parkinson's disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations. A randomized, double-blind, multicentre study

✍ G. Fénelon; S. Giménez-Roldán; J. L. Montastruc; F. Bermejo; F. Durif; I. Bourde 📂 Article 📅 2003 🏛 Springer 🌐 English ⚖ 121 KB

2.211 The SENSE study: An open-label, si

2.211 The SENSE study: An open-label, single-arm, multicentre, 6-week study evaluating the efficacy and safety of levodopa/carbidopa/entacapone (Stavelo) in Parkinson's disease patients experiencing early re-emergence of symptoms due to wearing-off with conventional medication

✍ W.H. Oertel; K. Eggert; Ö. Skogar; K. Amar; L. Luotonen; H. Nissinen 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 54 KB

Combining entacapone with levodopa/DDCI

Combining entacapone with levodopa/DDCI improves clinical status and quality of life in Parkinson’s Disease (PD) patients experiencing wearing-off, regardless of the dosing frequency: results of a large multicentre open-label study

✍ M. Onofrj; A. Thomas; F. Vingerhoets; W. Martin; S. Giménez-Roldán; J.-P. Azulay 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 292 KB

An open-label, multicentre clinical tria

An open-label, multicentre clinical trial to determine the levodopa dose-sparing capacity of pramipexole in patients with idiopathic Parkinson's disease

✍ M. M. Pinter; A. W. F. Rutgers; E. Hebenstreit; on behalf of the the study cente 📂 Article 📅 2000 🏛 Springer 🌐 English ⚖ 198 KB